Introduction
============

Mesenchymal stromal cells (MSCs) can be isolated from various tissues, such as bone marrow, adipose tissue, dental pulp, pancreas and spleen.^[@bib1]^ MSCs show enormous expansion potential when cultured *in vitro* and can differentiate into osteoblasts, adipocytes and chondrocytes, which play important roles in tissue regeneration and damage repair.^[@bib2]^ Due to the recent exciting discoveries that MSCs have immunomodulatory properties, these cells have attracted significant attention for their potential to treat immune related diseases, such as graft-*versus*-host disease (GVHD), liver diseases, autoimmune diseases and tissue inflammation.^[@bib3],[@bib4],[@bib5]^ MSCs have been reported to suppress T cell responses, including activation, proliferation and inflammatory cytokine production.^[@bib6]^ Some studies have suggested that MSCs also inhibit the cytotoxic activity of natural killer cells, regulate the maturation and function of B cells and help determine the polarization of macrophages.^[@bib7]^ Moreover, MSCs possess the anti-inflammatory and immunomodulatory effects and have been used to treat autoimmune diseases in clinical trials.^[@bib8]^

Regulatory T (Treg) cells play important roles in controlling immunologic tolerance and immune system homeostasis.^[@bib9]^ Aggarwal and Pittenger^[@bib7]^ reported that CD4^+^CD25^+^ Treg cells were increased when peripheral blood mononuclear cells (PBMCs) were cocultured with MSCs. Subsequently, Di Ianni *et al.*^[@bib10]^ extensively cocultured human MSCs (hMSCs) with different T-cell subsets, including CD4^+^CD25^+^, CD4^+^CD25^+^CD45RA^+^ and CD4^+^CD25^+^CD45RO^+^ T cells, and found that hMSCs could recruit, modulate and maintain the function and phenotype of Treg cells over time. Mechanistically, MSCs-derived TGF-β and PGE2 are key regulators involved in Treg cell induction.^[@bib11],[@bib12]^ Recently, Mougiakakos *et al.*^[@bib13]^ found that hMSCs could induce non-FOXP3-expressing CD4^+^ Treg cells, IL-10^+^ type 1 Treg cells and TGF-β^+^ Treg cell subsets in an HO-1-dependent fashion.

Although the best characterized Treg cells have the CD4^+^CD25^+^ phenotype, CD8^+^ T-cell populations have also been shown to possess immunosuppressive function, including CD8^+^CD28^−^, CD8^+^CD25^+^ and CD8^+^IL-10^+^ T cells, which can inhibit the activation and proliferation of lymphocytes.^[@bib12],[@bib14],[@bib15]^ CD8^+^CD28^−^ T cells have been reported to be antigen-specific, limited in their proliferative capacity and susceptible to programmed cell death.^[@bib16],[@bib17]^ These cells accumulate with aging, probably because of the continuous exposure to foreign antigens.^[@bib18],[@bib19],[@bib20]^ CD8^+^CD28^−^ T cells have recently attracted interest for their critical roles in various chronic immune disorders, such as Graves\'s disease, rheumatoid arthritis and type 1 diabetes mellitus.^[@bib21],[@bib22],[@bib23]^ Growing evidence have also suggested that CD8^+^CD28^−^ T cells can induce tolerance in transplantation, displaying immunosuppressive functions in renal or liver transplantations, as well as other organ transplantations.^[@bib24],[@bib25]^

The induction of Treg cells in CD4^+^T cell subsets by MSCs has been studied extensively; however, limited information exists concerning the effects of MSCs on CD8^+^CD28^−^ Treg cells.^[@bib12],[@bib26]^ Furthermore, although our previous clinical study demonstrated that the MSC treatment-induced clinical improvement of chronic GVHD (cGVHD) was accompanied by upregulation of CD8^+^CD28^−^ T cells,^[@bib27]^ the mechanisms underlying MSCs affecting the frequency and function of CD8^+^CD28^−^ Treg cells are still poorly understood.

Hence, we explored the effects and potential mechanisms of MSCs on the proportion and immunomodulatory functions of CD8^+^CD28^−^ Treg cells.

Materials and methods
=====================

MSCs isolation, expansion and characterization
----------------------------------------------

Ethical approval for this study was obtained from the ethics committee of Zhongshan Medical School (Sun Yat-sen University). Heparin-treated bone marrow was obtained by an iliac crest aspiration from healthy donors with informed consent. The MSCs were cultured and characterized as described previously.^[@bib28]^ The MSCs differentiated into osteoblasts and adipocytes under special culture conditions ([Supplementary Figure 1a--c](#sup1){ref-type="supplementary-material"}) and expressed CD29, CD44, CD73, CD90, CD105, but not CD34 or CD45 (all relevant monoclonal antibodies were purchased from BD Biosciences Pharmingen, Franklin Lakes, NJ, USA; [Supplementary Figure 1d](#sup1){ref-type="supplementary-material"}). All the MSCs used in this study were at passage 5.

Antibodies and flow cytometry
-----------------------------

The cells were stained with fluorochrome-coupled monoclonal antibodies (mAbs) according to the manufacturers\' recommendations. The following mAbs were obtained from BD Bioscience (San Jose, CA, USA): FITC-conjugated anti-CD3, PE-Cy7-conjugated anti-CD28, PE-conjugated anti-CD4, APC-Cy7-conjugated anti-CD25, APC-conjugated anti-CD8, V500-conjugated anti-CD8, PE-conjugated anti-tumor necrosis factor-related apoptosis inducing ligand (TRAIL), APC-conjugated anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and APC-conjugated anti-IL-10. FITC Annexin V Apoptosis Detection Kit was purchased from BD Pharmingen (San Jose, CA, USA). The Alexa Fluor 488-conjugated anti-TGF-β was purchased from R&D Systems (Minneapolis, MN, USA). The PE-conjugated anti-FasL was purchased from eBioscience (San Diego, CA, USA). The flow cytometry analyses were performed using a Gallios flow cytometer (Beckman Coulter, Fullerton, CA, USA) and a BD Bioscience Influx cell sorter, and the data were analyzed with the Kaluza software (Beckman Coulter) and FlowJo7.5 (Treestar, Ashland, OR, USA).

PBMCs isolation and cell sorting
--------------------------------

Heparinized peripheral blood samples were acquired from healthy donors and cGVHD patients with written informed consent. The PBMCs were collected by Ficoll-Hypaque density gradient centrifugation and resuspended in tissue culture medium (RPMI-1640 medium (Hyclone, Logan, UT, USA) supplemented with 10% (v/v) fetal bovine serum, 50 U/ml penicillin, and 50 U/ml streptomycin). For the cell sorting, the PBMCs were stained with FITC-conjugated anti-CD3, PE-Cy7-conjugated anti-CD28, PE-conjugated anti-CD4, APC-Cy7-conjugated anti-CD25 or APC-conjugated anti-CD8 antibody. The CD3^+^ T cells, CD3^+^CD4^+^CD25^−^ T cells and CD3^+^CD8^+^CD28^−^ T cells were sorted by FACS (BD Bioscience Influx, Franklin Lakes, NJ, USA). The purities of the sorted cells were \>95%.

Coculture experiments
---------------------

The MSCs (1×10^5^ cells/well) were seeded in 24-well flat-bottom plates and incubated for 24 h. T cells were added at different ratios and the increased effect was found optimal for the MSCs/T ratio of 1∶5. The CD3^+^ T cells (5×10^5^ cells/well) were added on the following day and cells were cocultured for 3 and 6 days. In order to exclude the effects of CD4^+^ T help cells,^[@bib29]^ we cocultured the CD3^+^CD8^+^ T cells (5×10^5^ cells/well) with MSCs (1×10^5^ cells/well) for 3 and 6 days. The cells were harvested and stained with APC-conjugated anti-CD8 and PE-Cy7-conjugated anti-CD28 antibodies, and the CD8^+^CD28^−^ T-cell subpopulation was detected by flow cytometry. For the investigation of CD8^+^CD28^−^ T cells\' function, CD8^+^CD28^−^ T cells were purified using FACS (BD Bioscience Influx) from CD3^+^CD8^+^ T cells cultured with or without MSCs. All the lymphocytes were cultured in RPMI-1640 containing 10% (v/v) fetal bovine serum, 50 U/ml penicillin and 50 U/ml streptomycin.

Proliferation assays
--------------------

Purified CD3^+^CD4^+^CD25^−^ T cells (naive T cells) were stained with 5 µM 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE, CellTrace; Invitrogen, Carlsbad, CA, USA). The CFSE-labeled naive T cells (2×10^5^ cells/well) and CD3^+^CD8^+^CD28^−^ T cells from the conditional cultures incubated with or without MSCs were seeded into 96-well microplates, treated with 200 ng/ml anti-CD3 mAb at 4 °C overnight, at ratios of 1∶0, 1∶1, 2∶1, 5∶1 and 10∶1 in a total volume of 200 µl of complete medium in the presence of 1 µg/ml CD28 mAb. After 4 days, the percentage of proliferating CD4^+^T cells was detected by CFSE dilution, as described above. In each experiment, the naive CD4^+^ T cells and CD8^+^CD28^−^ T cells were obtained from the same donor. To investigate the activation of the naive T cells, we evaluated two early activation markers of CD4^+^ T cells, CD69 and CD25, in the similar coculture system of naive CD4^+^ T cells and CD8^+^CD28^−^ T cells at different ratios with anti-CD3 mAb 200 ng/ml and IL2 100 U/ml for 24 h.

Cytokine assays
---------------

For the analysis of intracellular cytokine production, the CD4^+^CD25^−^ T cells were cocultured with CD8^+^CD28^−^ T cells that had been exposed to the conditional cultures in the presence or absence of MSCs. The cells were seeded into 96-well microplates, treated with 200 ng/ml anti-CD3 mAb at 4 °C overnight, at ratios of 1∶0, 1∶1, 2∶1, 5∶1 and 10∶1. The cells were then restimulated with the leukocyte activation cocktail (GolgiPlug; BD Pharmingen) for 6 h and IFN-γ production by CD4^+^ T cells was detected by flow cytometry according to gating on CD4^+^ T cells.

Apoptosis assays
----------------

Purified CD3^+^CD4^+^CD25^−^ T cells (naive CD4^+^ T cells) were seeded in pre-treated plates (as described for the proliferation assays), stimulated with 100 U/ml IL-2 for 2 days and then harvested. The CD25^+^ T cells (activated CD4^+^ T cells) and CD25^−^ T cells (non-activated CD4^+^ T cells) were isolated by FACS (BD Bioscience Influx). The activated CD4^+^ T cells (1×10^5^ cells/well) were incubated with sorted CD8^+^CD28^−^ T cells or MSCs-pre-treated CD8^+^CD28^−^ T cells in 96-well V-bottom plates at ratios of 1∶0, 1∶1, 2∶1, 5∶1 and 10∶1. After 6 h, the cells were harvested and labeled with APC-conjugated anti-CD8, FITC-conjugated anti-Annexin V antibody and propidium iodide (BD Biosciences). The cytotoxicity of the CD8^+^CD28^−^T cells was evaluated as the percentage of Annexin V-positive CD4^+^ T cells.

The apoptosis ratio of CD8^+^CD28^−^ T cells was also evaluated by hypodiploid DNA content analysis.^[@bib30]^ Purified CD8^+^CD28^−^ T cells cultured in the presence or absence of MSCs were harvested, fixed with cold 75% ethanol overnight and resuspended in PBS contained 0.2% saponin, 50 μg/ml propidium iodide and 10 μg/ml RNaseA, then analyzed by flow cytometry after incubation for 30 min in the dark.

Blocking studies
----------------

The neutralizing antibodies, anti-IL-10 (10 µg/ml) and anti-TGF-β (1 µg/ml), were added at the start of the culture periods for the proliferation, activation and cytokine assays. For the apoptosis assays, the anti-FasL (10 µg/ml) or anti-PD-L1 (10 µg/ml) neutralizing antibodies were added. Additionally, 1 mM 1-MT (Sigma, St Louis, MO, USA), 10 µg/ml anti-IL-6 mAb (R&D Systems), 1 µM Indomethacin (Sigma), 1 µM NS398 (Sigma) or anti-TGF-β (1 µg/ml) was separately added to the coculture system of the CD3^+^CD8^+^ T cells and MSCs.

Chronic GVHD patients\' characteristic and MSCs infusion
--------------------------------------------------------

Patients with chronic GVHD met the National Institutes of Health consensus criteria for diagnosis and classification of chronic GVHD patients for clinical trials that detail described in our previous study.^[@bib28]^ Clinical data of all patients are summarized in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. In addition to the original immunosuppressive therapy, the recruited patients received three infusions (at 4-week intervals) of MSCs derived from third-party healthy donors. The dose of MSCs was 1×10^6^ cells/kg/infusion. Heparinized peripheral blood was obtained from these patients before MSCs treatment and 3 months after the first MSCs infusion. All patients were provided written informed consent.

Statistical analysis
--------------------

The results were given as the means±s.d. of the independent experiments. The statistical analyses were performed using SPSS v. 17.0 (SPSS Inc. Chicago, IL, USA). The data obtained on the effects of the MSCs on CD8^+^CD28^−^ T cells under different culture conditions were compared using paired *t*-tests.

Results
=======

MSCs increase the frequency of CD8^+^CD28^−^ T cells
----------------------------------------------------

To assess the effects of the MSCs on the proportion of CD8^+^CD28^−^ T cells in culture, purified CD3^+^ T cells were cultured with or without MSCs at a ratio of 5∶1. We found that MSCs significantly increased the frequency of CD8^+^CD28^−^ T cells in the CD3^+^ T-cell population after 3 days of coculture (18.28%±2.64% *versus* 13.14%±1.18% of CD3^+^ T cells alone, *P*=0.029). The frequency of CD8^+^CD28^−^ T cells after 6 days culture was still higher when the cells were cultured in the presence of MSCs (13.44%±1.97%% *versus* 10.49%±1.17% of CD3^+^ T cells alone, *P*=0.036) ([Figure 1a and b](#fig1){ref-type="fig"}). To avoid the possible interference of CD4^+^ T cells in the coculture system,^[@bib29]^ Purified CD3^+^CD8^+^ T cells were cocultured with or without MSCs. Consistently, the much higher frequency of the CD8^+^CD28^−^ T cells was exhibited in the presence of MSCs (20.08%±1.86%) after 3 days than that in absence of MSCs (14.04%±1.23% *P*=0.001). In addition, the frequency of the CD8^+^CD28^−^ T cells presented the same tendency after 6-days culture (12.68%±1.27% with MSCs *versus* 10.9%±1.46% without MSCs, *P*=0.038) ([Figure 1c and d](#fig1){ref-type="fig"}).

MSCs enhance the immunosuppressive functions of CD8^+^CD28^−^ T cells on inhibiting the proliferation and activation of CD4^+^CD25^−^ T cells
---------------------------------------------------------------------------------------------------------------------------------------------

Previous studies have demonstrated that CD8^+^CD28^−^ Treg cells possessed immune regulatory effects on T-cell responses, and displayed immunosuppressive roles in autoimmune diseases.^[@bib17],[@bib21],[@bib31]^ To investigate whether the MSCs could affect the immunosuppressive function of the CD8^+^CD28^−^ T cells, we set up a coculture system for evaluating regulatory effect on T-cell proliferation, using CD4^+^CD25^−^ T cells as responder cells. As shown in [Supplementary Figure 2a](#sup1){ref-type="supplementary-material"}, CD4^+^CD25^−^ T cells were well proliferated at on the day 4 in the presence of anti-CD3 mAb and anti-CD28 mAb. And the proliferation was inhibited when the CD8^+^CD28^−^ T cells were added ([Supplementary Figure 2b](#sup1){ref-type="supplementary-material"}). The CD8^+^CD28^−^ T cells strongly suppressed the CD4^+^ T cell proliferation at a ratio of 1∶1 (CD4^+^CD25^−^ T responder cells, 72.13%±1.97% *versus* 56.76%±2.03% *P*=0.003), but showed a weaker (and non-significant) effect at a ratio of 1∶10 (CD4^+^CD25^−^ T responder cells, 72.13%±1.97% *versus* 70.73%±1.86% *P*=0.567) ([Supplementary Figure 2b](#sup1){ref-type="supplementary-material"}). Next, we pre-treated the CD8^+^ T cells with MSCs for 3 days at a ratio of 5∶1, and then sorted the CD8^+^CD28^−^ T cells, which was followed by coculturing with the CD4^+^CD25^−^ T responder cells at a ratio of 1∶1. The MSCs-pre-treated CD8^+^CD28^−^ T cells yielded a significantly lower percentage of proliferating CD4^+^ T cells (51.84%±3.86%) compared with the untreated CD8^+^CD28^−^ T cells (58.48%±3.95%, *P*=0.038) ([Figure 2a and b](#fig2){ref-type="fig"}).

Treg cells show the ability of inhibiting the activation of T cells when they response to foreign or self-antigens.^[@bib32]^ Therefore, we next used CD69 and CD25, which were generally regarded as surface-activation markers of T cells,^[@bib33]^ to examine the effects of the CD8^+^CD28^−^ T cells on the activation of naive CD4^+^ T cells. As shown in [Supplementary Figure 2c and d](#sup1){ref-type="supplementary-material"}, the expression of CD69 and CD25 on CD4^+^ T cells reached a high level 24 h after stimulation, and they were significantly and dose-dependently reduced through cocultured with CD8^+^CD28^−^ T cells. Furthermore, MSCs-pre-treated CD8^+^CD28^−^ T cells significantly inhibited the expression of CD69 (CD8^+^CD28^−^ T cells after MSCs pre-treatment, 32.95%±1.42% *versus* 40.12%±1.21% *P*=0.005) and CD25 (CD8^+^CD28^−^ T cells after MSCs pre-treatment, 15.54%±1.14% *versus* 23.19%±1.67% *P*=0.024) on CD4^+^T cells compared with CD8^+^CD28^−^ T cells that had not been exposed to the MSCs ([Figure 2c--f](#fig2){ref-type="fig"}).

Taken together, these findings suggest that the MSCs may enhance the ability of CD8^+^CD28^−^ T cells to inhibit the proliferation and activation of the CD4^+^CD25^−^ T cells.

MSCs enhance the ability of CD8^+^CD28^−^ T cells to inhibit IFN-γ production by responder CD4^+^ T cells
---------------------------------------------------------------------------------------------------------

Inhibiting inflammatory cytokine production by CD4^+^ T cells is one of the immunomodulatory functions of CD8^+^CD28^−^ T cells.^[@bib31]^ To investigate whether MSCs can enhance the immunosuppressive ability of CD8^+^CD28^−^ T cells, we assessed the ability of MSCs-pre-treated and monocultured CD8^+^CD28^−^ T cells to modulate the production of IFN-γ by CD4^+^ T cells. As shown in [Supplementary Figure 3a](#sup1){ref-type="supplementary-material"}, CD8^+^CD28^−^ T cells dose-dependently inhibited the IFN-γ production by activated CD4^+^ T cells, with the maximum inhibition observed at a ratio of 1∶1 (activated CD4^+^ T cells, 26.37%±4.03% *versus* 19.34%±4.96% *P*=0.007). Furthermore, CD4^+^ T cells produced even less IFN-γ when cocultured with MSCs-pre-treated CD8^+^CD28^−^ T cells, compared with CD8^+^CD28^−^ T cells that had not been exposed to MSCs (CD8^+^CD28^−^ T cells after MSCs pre-treatment, 15.8%±5.27% *versus* 19.34%±4.96% *P*=0.003) ([Figure 3a and b](#fig3){ref-type="fig"}).

MSCs enhance the capacity of CD8^+^CD28^−^ T cells to induce apoptosis in activated CD4^+^ T cells
--------------------------------------------------------------------------------------------------

Because CD4^+^CD25^+^Foxp3^+^ Treg cells could induce apoptosis of responder T cells,^[@bib34]^ we then studied the ability of CD8^+^CD28^−^ T cells on inducing apoptosis of activated CD4^+^ T cells, and further tested whether MSCs could enhance this function. As shown in [Supplementary Figure 3b](#sup1){ref-type="supplementary-material"}, the CD8^+^CD28^−^ T cells dose-dependently induced apoptosis in the activated CD4^+^CD25^+v^T cells (as assessed by Annexin V positivity). In contrast, the CD4^+^CD25^−^ non-activated T cells were resistant to the CD8^+^CD28^−^ T cell-mediated cytotoxicity ([Supplementary Figure 3c](#sup1){ref-type="supplementary-material"}). Compared with the CD8^+^CD28^−^ T cells, the MSCs-pre-treated CD8^+^CD28^−^ T cells induced apoptosis in a larger proportion of the activated CD4^+^ T cells (19.77%±4.83% *versus* 23.98%±3.97% of CD8^+^CD28^−^ T cells after MSCs pre-treatment; *P*=0.017) ([Figure 3c and d](#fig3){ref-type="fig"}).

MSCs enhance the immune regulatory functions of CD8^+^CD28^−^ T cells by increasing the expression levels of IL-10 and FasL
---------------------------------------------------------------------------------------------------------------------------

The above findings showed that MSCs efficiently enhanced the immunosuppressive activity of CD8^+^CD28^−^ T cells. As previous studies have shown that TGF-β or IL-10 involved in the functions of Treg cells,^[@bib31]^ we used blocking antibodies against TGF-β (1 µg/ml) or IL-10 (10 µg/ml) to detect the CD8^+^CD28^−^ Treg cells activity on the proliferation, activation, and IFN-γ production of responder CD4^+^ T cells. Our results showed that CD8^+^CD28^−^ T cells partially lost their immunosuppressive ability when anti-TGF-β or anti-IL-10 neutralizing antibody was added to the coculture system respectively ([Supplementary Figure 4a--h](#sup1){ref-type="supplementary-material"}). Based on these findings, we further evaluated the expression levels of TGF-β and IL-10 in the CD8^+^CD28^−^ T cells obtained from the CD8^+^ T cells cocultured with MSCs. We found that there was no difference in the levels of TGF-β expression with or without MSCs coculture (3.02%±0.36% *versus* 2.85%±1.09% of CD8^+^ T cells alone; *P*=0.77) ([Figure 4a](#fig4){ref-type="fig"}). However, IL-10 production was higher in the CD8^+^CD28^−^ T cells obtained from the MSCs-pre-treated CD8^+^ T cells compared with the monocultured CD8^+^ T cells (percentage: 5.44%±0.18% *versus* 2.41%±0.18% of CD8^+^ T cells alone; *P*=0.003; MFI: 148.43±2.93 *versus* 118.62±8.01 of CD8^+^ T cells alone; *P*=0.011) ([Figure 4b](#fig4){ref-type="fig"}).

Because the FasL/Fas and PD-L1/PD-1 pathways represent common apoptotic signaling pathways in many cell types,^[@bib35],[@bib36]^ we hypothesized that these pathways might be involved in the CD8^+^CD28^−^ T cell-mediated the apoptosis of CD4^+^T cells. We thus added blocking antibodies against FasL and PD-L1 to coculture system and performed cytotoxicity experiments. The apoptosis of CD4^+^ T cells was reduced by the treatment of CD8^+^CD28^−^T cells with anti-FasL neutralizing antibody, rather than anti-PD-L1 ([Supplementary Figure 4i and j](#sup1){ref-type="supplementary-material"}). We also evaluated the expression of FasL and PD-L1 on the CD8^+^CD28^−^ T cells cultured with or without MSCs, and found that FasL expression was higher in the presence of the MSCs (percentage: 3.98%±0.87% *versus* 2.0%±0.48% of CD8^+^ T cells alone; *P*=0.045; MFI: 41.59±3.7 *versus* 37.22±4.53 of CD8^+^ T cells alone; *P*=0.02) ([Figure 4c](#fig4){ref-type="fig"}). In contrast, the PD-L1 expression did not differ significantly in the presence or absence of the MSCs (1.81%±0.0.21% *versus* 1.71%±0.25% of CD8^+^ T cells alone; *P*=0.10) ([Figure 4d](#fig4){ref-type="fig"}). We also detected the other factors potentially involved in the killing activity of Treg cells, such as the CTLA-4 and the TRAIL, and found no obvious change in the presence or absence of the MSCs ([Figure 4e and f](#fig4){ref-type="fig"}).

To gain insight into the mechanism of how MSCs-mediated the expressions of IL-10 and FasL on CD8^+^CD28^−^ T cells, we tested several potential mediators using monoclonal neutralizing antibodies specific for IL-6 and TGF-β, specific inhibitors for IDO (1-MT) or cyclooxygenase (NS398 for COX2 or Indomethacin for COX1 and COX2). Unfortunately, as shown in [Supplementary Figures 5](#sup1){ref-type="supplementary-material"} and [6](#sup1){ref-type="supplementary-material"}, neither inhibitors nor neutralizing antibodies tested showed obvious effects on the expressions of IL-10 or FasL of CD8^+^CD28^−^ T cells after cocultured with MSCs.

MSCs increase the percentage of CD8^+^CD28^−^ T cells by decreasing their rate of apoptosis partially through IL-6
------------------------------------------------------------------------------------------------------------------

To further understand how MSCs increased the proportion of CD8^+^CD28^−^ T cells, we performed a kinetic experiment to monitor the changes in the percentage of CD8^+^CD28^−^ T cells among the total CD8^+^ T-cell population as culturing CD3^+^CD8^+^ T cells with or without MSCs for 4 days. Interestingly, although the frequency of CD8^+^CD28^−^ T cells decreased gradually over time both in the presence and absence of MSCs, the proportion of CD8^+^CD28^−^ T cells was higher in the coculture system with the MSCs at the corresponding time point, and showed a significant difference on the third day ([Figure 5a](#fig5){ref-type="fig"}). Consequently, we explored the possible reasons for the MSCs affecting increase of proportion CD8^+^CD28^−^ T cells. Firstly, we investigated whether the MSCs could shift the CD8^+^CD28^+^ T cells toward CD8^+^CD28^−^ T cells, and we cocultured purified CD3^+^CD8^+^CD28^+^ T cells with or without MSCs (ratio of 5∶1) for 3 days. The percentage of CD28^+^T cells did not significantly differ between these cultures, suggesting that the MSCs may not directly shift the CD8^+^CD28^+^ T cells to the regulatory phenotype ([Figure 5b](#fig5){ref-type="fig"}). Secondly, we addressed whether MSCs could promote the proliferation of the CD8^+^CD28^−^ T cells. CFSE-labeled CD8^+^CD28^−^ T cells and CD8^+^CD28^+^ T cells were cultured with or without MSCs (5∶1) in the presence of PHA (5 µg/ml) for 4 days. However, MSCs inhibited the proliferation of the CD8^+^CD28^−^ T and CD8^+^CD28^+^ T cells to similar degrees ([Figure 5c](#fig5){ref-type="fig"}). Thus, we then examined the influence of the MSCs on the apoptosis of the CD8^+^CD28^−^ T and CD8^+^CD28^+^ T cells. The percentage of viable cells (those negative for Annexin V and propidium iodide staining) was significantly higher in the CD8^+^CD28^−^ T cells cocultured with MSCs compared with the monocultures, whereas the viability of the CD8^+^CD28^+^ T cells was similar in the cultures with and without the MSCs ([Figure 5d](#fig5){ref-type="fig"}). To further confirm this result, we detected the apoptosis of CD8^+^CD28^−^ T cells by hypodiploid DNA content analysis^[@bib30]^ and observed similar result ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Taken together, MSCs significantly inhibit CD8^+^CD28^−^ T cells apoptosis. To explore the factors involved in the MSCs-enhanced survival of the CD8^+^CD28^−^ T cells, we cocultured CD8^+^T cells and MSCs in the presence of neutralizing antibodies against IL-6 or TGF-β or specific inhibitors of cyclooxygenase (NS398 and Indomethacin) or IDO (1-MT). We found that both the MSCs-mediated decrease of CD8^+^CD28^−^ T cells apoptosis ([Figure 6a and b](#fig6){ref-type="fig"}) and the increase in the frequency of CD8^+^CD28^−^ T cells ([Figure 6c](#fig6){ref-type="fig"}) could be partially blocked by the neutralizing antibody against IL-6, rather than the other tested agents. Collectively, our data strongly suggest that MSCs can increase the frequency of CD8^+^CD28^−^ T cells by decreasing their apoptosis partially through the IL-6 pathway.

Clinical efficacy of hMSCs correlates with the frequency of CD8^+^CD28^−^ T cells in cGVHD patients
---------------------------------------------------------------------------------------------------

To investigate the effects of MSCs on CD8^+^CD28^−^ T cells *in vivo*, samples of 13 cGVHD patients who received three infusions of MSCs were analyzed. In the calculation of the maximum response for the 6-month follow-up period, three patients had a complete response (CR), seven patients had a partial response (PR) and three patients had a non-response (NR) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Because the best therapeutic effects were observed 3 months after the first MSCs infusion, we analyzed the changes of CD8^+^CD28^−^ T cells at this time point. Compared with the pre-treatment, the frequency of CD8^+^CD28^−^ T cells within the CD8^+^ T-cell population was markedly increased (from 31.84%±12.48% to 42.59%±15.71%, *P*=0.005) ([Supplementary Figure 8a and b](#sup1){ref-type="supplementary-material"}), whereas no significant change was observed in the NR cGVHD patients ([Supplementary Figure 9](#sup1){ref-type="supplementary-material"}). A detailed analysis of the expression of IL-10 and FasL on CD8^+^CD28^−^ T cells was conducted in CR/PR patients. As shown in [Supplementary Figure 8c--f](#sup1){ref-type="supplementary-material"}, after MSCs treatment, the frequency of CD8^+^CD28^−^ IL-10^+^ T cells was increased (from 1.7%±0.62% to 6.21%±1.04%, *P*=0.02), and the frequency of CD8^+^CD28^−^FasL^+^ T cells was increased from 1.15%±0.39% to 4.43%±0.96% (*P*=0.012). Taken together, these results suggest that the clinical improvement is accompanied by an increase of CD8^+^CD28^−^ T cells in the CR/PR cGVHD patients.

Discussion
==========

The main findings of this study are that MSCs can effectively enhance the immunomodulatory function of CD8^+^CD28^−^ T cells by inhibiting naive CD4^+^ T-cell proliferation and activation, decreasing the production of IFN-γ by activated CD4^+^ T cells and inducing apoptosis in activated CD4^+^T cells. Moreover, our results indicate that the MSCs increase the proportion of the CD8^+^CD28^−^ T cells by reducing their rate of apoptosis.

Accumulating evidence have demonstrated that the CD8^+^CD28^−^ T-cell subpopulation displayed a regulatory role in diverse diseases or conditions, such as cancer,^[@bib37]^ transplant rejection,^[@bib38]^ autoimmune diseases and experimentally induced inflammatory bowel disease.^[@bib21]^ Functional studies have reported that CD8^+^CD28^−^ T cells can dose-dependently inhibit the proliferation and IFN-γ production of responder CD4^+^ T cells.^[@bib31],[@bib39]^ Our observation also demonstrated that the CD8^+^CD28^−^ T cells showed an immunosuppressive function. Moreover, this study demonstrated that CD8^+^CD28^−^ T cells could induce apoptosis in activated CD4^+^ T cells and decrease the expression levels of the early activated antigens, CD25 and CD69, on CD4^+^ T cells, which suggested that the CD8^+^CD28^−^ T cells possessed pleiotropic immunosuppressive effects similar to those of traditional Treg cells.^[@bib34]^

Most of the *in vitro* and *in vivo* studies have suggested that MSCs performed the immunomodulatory function by the induction and expansion of Treg cells,^[@bib40]^ but few studies have addressed whether MSCs could affect the immunomodulatory functions of Treg cells. Although Prevosto *et al.*^[@bib12]^ reported that the MSCs-mediated immunomodulation was not associated with enhanced Treg cell activity, our study has demonstrated for the first time that MSCs could augment the CD8^+^CD28^−^ Treg cell activity by inhibiting naive CD4^+^ T-cell proliferation and activation, decreasing IFN-γ production by the activated CD4^+^ T cells and inducing apoptosis in the activated CD4^+^ T cells. These results were similar to the findings that injury-induced increase in CD4^+^CD25^+^ Treg cell activity by suppressing T-cell proliferation and Th1-type cytokine production.^[@bib41]^ Additionally, Choileain^[@bib41]^ *et al.* found that the injury-induced upregulation in Treg cell activity was cell-contact dependent and mediated partially by increased TGF-β1, rather than IL-10, expression.^[@bib41]^ Menager-Marcq *et al.*^[@bib31]^ found that the soluble immunosuppressive factors, TGF-β and IL-10, played crucial roles in the ability of CD8^+^CD28^−^ Treg lymphocytes to prevent murine colitis. Additionally, CD8^+^CD28^−^ Treg cells incapable of producing IL-10 lost the functional ability to prevent colitis. Consistent with these findings, we also observed that the CD8^+^CD28^−^ T-cell inhibition of the CD4^+^ T-cell proliferation was mediated by both TGF-β and IL-10. In contrast, IL-10 alone rather than TGF-β participated in the inhibition of naïve CD4^+^ T-cell activation and inflammatory cytokine secretion, which was supported by the observation that only anti-IL-10, and not anti-TGF-β antibodies, blocked the related ability of the CD8^+^CD28^−^ Treg cells. Furthermore, when CD8^+^CD28^−^ Treg cells were cultured with MSCs, the expression of IL-10, rather than TGF-β was increased moderately, which implied that the MSCs might enhance the immunosuppressive activity of the CD8^+^CD28^−^ Treg cells through increased IL-10 production.

The decrease of cytotoxic cells is thought to be another mechanism of Treg cells suppression by the induction of apoptosis in effector cells. FasL, a type-II transmembrane protein which belongs to the tumor necrosis factor family, is mostly expressed on activated T cells and induces apoptosis upon binding with its receptor.^[@bib34]^ Meanwhile, the PD-1/PD-L1 pathway performs a crucial role in inhibiting T-cell responses, enhancing T-cell tolerance and preventing immune disorders.^[@bib42]^ Other factors potentially involved in the killing activity of Treg cells include the CTLA-4 and the TRAIL.^[@bib43],[@bib44]^ The question is which pathways are related with the CD8^+^CD28^−^ T cell-mediated CD4^+^ T-cell apoptosis? In the present work, blocking the Fas/FasL interaction decreased the apoptosis of activated CD4^+^ T cells when cultured with CD8^+^CD28^−^ T cells *in vitro*, whereas an abrogation of the PD-1/PD-L1 interaction did not show any obvious suppression of the apoptosis of the responder T cells. Furthermore, the MSCs enhanced the killing activity of the CD8^+^CD28^−^ Treg cells through an upregulation of FasL, rather than PD-L1 expression. Collectively, this evidence supported the hypothesis that MSCs might enhance the regulatory function of the CD8^+^CD28^−^ T cells by increasing the expression of IL-10 and FasL, and future studies should address the potential mechanisms of CD8^+^CD28^−^ Treg cells function after the treatment with MSCs.

Another question is how the MSCs increase the proportion of CD8^+^CD28^−^ T cells in the coculture system. Although, several groups have been reported that MSCs affect the percentage of CD8^+^CD28^−^ T cells after cocultured with CD3^+^CD8^+^ T cells, but the mechanism still need to be elucidated.^[@bib29],[@bib45]^ CD8^+^CD28^−^ T cells are considered to be antigen-specific, terminally differentiated, senescent and with shortened telomeres. The present concept that CD8^+^CD28^−^ T cells lack the ability of proliferation after antigen stimulation has been challenged by several groups who have demonstrated that these T cells also possess the ability of proliferation under certain stimulation conditions. We verified for the first time that the coculture with MSCs did not promote the proliferation of CD8^+^CD28^−^ T cells or the shift from CD8^+^CD28^+^ T cells to a CD8^+^CD28^−^ T cells phenotype, whereas the MSCs increased the percentage of CD8^+^CD28^−^ T cells by reducing their apoptosis. This observation were similar with previous study that CD8^+^CD28^−^ T cells were prone to apoptosis^[@bib46]^ because their telomerase activity is decreased by repeated antigenic stimulation.^[@bib47]^ The kinetic analysis of the proportion of CD8^+^CD28^−^ T cells in the CD8^+^ T cell population showed that the frequency of CD8^+^CD28^−^ T cells decreased over time, possibly due to their shortened telomeres. Moreover, the protective action of MSCs on CD8^+^CD28^−^ T cells occurred partially through the action of IL-6, which has been demonstrated to play a crucial role in the suppression of lymphocyte apoptosis by MSCs.^[@bib48]^ Additionally, IL-6 has pleiotropic function on preventing the death of resting T cells and activated T cells under certain stimulus.^[@bib49],[@bib50]^ However, blocking IL-6 did not fully abrogate the anti-apoptotic function of the MSCs on the CD8^+^CD28^−^ T cells, indicating that some other mediators may not have been identified yet.

Increasing studies showed that the CD8^+^CD28^−^ T cells played an important role in various immune disorders such as cancer, chronic infections, autoimmune diseases and allogeneic transplantation. Our previous clinical study showed that the MSC treatment-induced clinical improvement of cGVHD was accompanied by the increasing ratio of CD8^+^CD28^−^/CD8^+^CD28^+^ T cells.^[@bib19]^ In this follow-up prospective observation of the MSC treatment of cGVHD patients, we also found an increase in CD8^+^CD28^−^ T cells in the CR/PR groups, but not in the NR group. Interestingly, clinical improvement was also accompanied by an increase of IL-10 and FasL expression on CD8^+^CD28^−^ T cells. However, a more complete understanding of the MSCs-induced enhancement of CD8^+^CD28^−^ Treg cell activity may be of major significance for elucidating the therapeutic mechanisms of MSCs for the treatment of cGVHD.

In conclusion, we herein demonstrate a new immunomodulatory activity of hMSCs: the modulation of CD8^+^CD28^−^ Treg cell function. MSCs can upregulate the percentage of CD8^+^CD28^−^ T cells, apparently by protecting them from apoptosis. Thus, our novel findings may facilitate the design of clinical studies and help establish novel monitoring procedures to reproducibly assess the efficacy of MSCs-based treatments in the future.
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![MSCs increase the percentage of CD8^+^CD28^−^ T cells. Representative flow cytometry dot plots of the percentage of CD28^−^ T cells by gating on CD8^+^ T cells among the purified CD3^+^ T cells (**a**) or among the purified CD3^+^CD8^+^ T cells (**c**) in the absence or presence of MSCs 3 or 6 days at the ratio of 5∶1, and higher percentages of CD28^−^ T cells were observed when cocultured with MSCs (**b**, **d**). The results are representative of four independent experiments. The bar graphs indicate the means±s.d., statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01. MSC, mesenchymal stem cell.](cmi2014118f1){#fig1}

![The proliferation and activation of naive CD4^+^ T cells is markedly inhibited by the CD8^+^CD28^−^ T cells educated by MSCs. The T-cell proliferative response was evaluated by the CFSE dilution of the CFSE-labeled CD4^+^ T cells in the presence of anti-CD3 (200 ng/ml) and anti-CD28 (1 μg/ml). The CD8^+^CD28^−^ T cells and MSCs-pre-treated CD8^+^CD28^−^ T cells were added respectively at the ratio of 1∶1, and their inhibitory effects on T-cell proliferation were analyzed (**a**, **b**). The CD8^+^CD28^−^ T cells and MSCs-pre-treated CD8^+^CD28^−^ T cells were cocultured with naive CD4^+^ T cells at a ratio of 1∶1 in the presence of a stimulus for 24 h, and their effects on T-cell activation were determined by the expression of CD69 (**c**, **d**) and CD25 (**e**, **f**) on CD4^+^ T cells. The gray histograms correspond to the isotype controls. The bar graphs indicate the means±s.d. Statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01, *n*=3. CFSE, 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester; MSC, mesenchymal stem cell.](cmi2014118f2){#fig2}

![MSCs enhance the ability of CD8^+^CD28^−^ T cells to inhibit IFN-γ production by responder CD4^+^ T cells and induce the apoptosis of activated CD4^+^ T cells. Flow cytometry plots represent the levels of IFN-γ secreted by the CD4^+^ T cells. The CD8^+^CD28^−^ T cells and MSCs-pre-treated CD8^+^CD28^−^ T cells were added respectively at a ratio of 1∶1, and IFN-γ production was significantly downregulated by MSCs-pre-treated CD8^+^CD28^−^ T cells (**a**, **b**). The purified activated T cells (CD4^+^CD25^+^ T cells) were cocultured with CD8^+^CD28^−^ T cells and MSCs-pre-treated CD8^+^CD28^−^ T cells at a ratio of 1∶1, and the cytotoxity of CD8^+^CD28^−^ T cells was evaluated by Annexin V-positive cells within the total CD4^+^ T-cell population (**c**, **d**) The bar graphs indicate the means±s.d.; statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01, *n*=3. MSC, mesenchymal stem cell.](cmi2014118f3){#fig3}

![MSCs affect the functions of the CD8^+^CD28^−^ T cells partially by upregulating the expression of IL-10 and FasL. An analysis of the effector molecules that expressed by the CD8^+^CD28^−^ T cells in the presence or absence of MSCs, including TGF-β (**a**), IL-10 (**b**), FasL (**c**), PD-L1 (**d**), TRAIL (**e**) and CTL-A4 (**f**). The frequency and mean fluorescence intensity (MFI) of IL-10 and FasL were moderately increased by MSCs (**b**, **c**). The results are representative of three independent experiments. The bar graphs indicate the means±s.d. Statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01. CTLA-4, cytotoxic T-lymphocyte antigen 4; MSC, mesenchymal stem cell; TRAIL, tumor necrosis factor-related apoptosis inducing ligand.](cmi2014118f4){#fig4}

![MSCs increase the percentage of CD8^+^CD28^−^ T cells by decreasing the apoptosis. The kinetics of the relative percentages of CD8^+^CD28^−^ T cells were detected in purified CD8^+^ T cells cocultured with or without MSCs (**a**). MSCs increased the percentages of CD8^+^CD28^−^ T cells neither shift CD8^+^CD28^+^ T cells to CD8^+^CD28^−^ T cells (**b**), nor prior to promote the proliferation of CD8^+^CD28^−^ T cells (**c**), but decreased the apoptosis of CD8^+^CD28^−^ T cells (**d**). The bar graphs indicate the means±s.d.; statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01, *n*=3.](cmi2014118f5){#fig5}

![MSCs-mediated increase in the frequency of CD8^+^CD28^−^ T cells and the decrease of CD8^+^CD28^−^ T cells apoptosis were partially *via* IL-6. The frequency of viable CD8^+^CD28^−^ T cells was increased after cocultured with MSCs, and anti-IL-6 mAb partially reversed the MSCs-mediated effects on CD8^+^CD28^−^ T cell survival (**a**, **b**). Similarly, the frequency of CD8^+^CD28^−^ T cells among purified CD8^+^ T cells were increased in the presence of MSCs, and that increase was partially blocked by anti-IL-6 mAb (**c**). The bar graphs indicate the means±s.d.; statistically significant differences are indicated as follows: \**P*\<0.05 and \*\**P*\<0.01, *n*=3. mAb, monoclonal antibody; MSC, mesenchymal stem cell.](cmi2014118f6){#fig6}
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